Conference Proceedings
Clinical and Biological Indicators of Duvelisib Efficacy in CLL from the Phase 3 DUO™ Study
Jennifer R Brown, Ian W Flinn, Matthew S Davids, Peter Hillmen, Marco Montillo, Zsolt Nagy, Julio Delgado, Bryone J Kuss, Constantine S Tam, Ulrich Jaeger, Paolo Ghia, Stephan Stilgenbauer, Carol Moreno, NgocDiep Le, Stephanie Lustgarten, Kam Sprott, Jonathan A Pachter, David T Weaver, Florence Cymbalista
BLOOD | AMER SOC HEMATOLOGY | Published : 2018
Abstract
Abstract Introduction In CLL, the timing and selection of therapy is largely informed by disease stage, prognostic molecular features, tumor load, and patient (pt) performance status. Duvelisib (DUV) is a novel, oral, dual PI3K-δ,γ inhibitor in clinical development for the treatment of CLL/SLL, FL, and other hematologic malignancies. Results from the Phase 3 DUO study (NCT02004522) for relapsed/refractory CLL/SLL showed that DUV monotherapy resulted in statistically significant improvement over ofatumumab (OFA) monotherapy for median progression-free survival (mPFS; 13.3 vs 9.9 months (mo); p<0.0001), overall response rate (ORR; 73.8% vs 45.3%; p<0.0001), and ly..
View full abstract